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Abstract
Background
Low-grade gliomas affect younger adults and carry a favorable prognosis. They include a
variety of biological features affecting clinical behavior and treatment. Having no guidelines
on treatment established, we aim to describe clinical and treatment patterns of low-grade gli-
omas across the largest cancer database in the United States.
Methods
We analyzed the National Cancer Database from 2004 to 2015, for adult patients with a
diagnosis of World Health Organization grade II diffuse glioma.
Results
We analyzed 13,621 cases with median age of 41 years. Over 56% were male, 88.4% were
white, 6.1% were black, and 7.6% Hispanic. The most common primary site location was
the cerebrum (79.9%). Overall, 72.2% received surgery, 36.0% radiation, and 27.3% che-
motherapy. Treatment combinations included surgery only (41.5%), chemotherapy + sur-
gery (6.6%), chemotherapy only (3.1%), radiation + chemotherapy + surgery (10.7%),
radiation + surgery (11.5%), radiation only (6.1%), and radiotherapy + chemotherapy
(6.7%). Radiation was more common in treatment of elderly patients, 1p/19q co-deletion
(37.3% versus 24.3%, p<0.01), and tumors with midline location. Median survival was 11
years with younger age, 1p/19q co-deletion, and cerebrum location offered survival
advantage.
Conclusions
Tumor location, 1p/19q co-deletion, and age were the main determinants of treatment
received and survival, likely reflecting tumor biology differences. Any form of treatment was
preferred over watchful waiting in the majority of the patients (86.1% versus 8.1%). Survival
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Data Availability Statement: The data is provided
by the National Cancer Database and is available
upon request by the National Cancer Database for
investigators associated with Commission on
Cancer accredited institutions. The National Cancer
Database retains the decision of accessing the data
based on an application process. Association to a
Commission on Cancer accredited cancer program
is required for applying. The application process
opens throughout the year and requires a protocol
submission. We applied for and were granted
access to the data in the fall of 2017. Details on
of low-grade gliomas is higher than previously reported in the majority of clinical trials and
population-based analyses. Our analysis provides a real world estimation of treatment deci-
sions, use of molecular data, and outcomes.
Introduction
Low-grade gliomas have a wide variety of histologic and molecular features corresponding to a
grade II in the World Health Organization (WHO) Classification of Central Nervous System
Tumors[1]. This group includes astrocytomas, oligodendrogliomas, and oligoastrocytomas.
However, evidence of molecular genetic analyses demonstrates that the vast majority of tumors
previously classified as oligoastrocytomas have a genetic profile typical of either diffuse astro-
cytoma or oligodendroglioma, with few true cases of oligoastroctyomas[1]. Therefore this cate-
gory is now designed as NOS in the 2016 classification [2], and its use is expected to decrease.
Low-grade gliomas are most common in young adults between 35 and 44 years of age[3].
They are a slower growing group of tumors, but a subgroup can be fast growing; still their
prognosis is favorable compared to high-grade gliomas. However, most low-grade gliomas
eventually transform into high-grade gliomas, resulting in debate in determining the first
course of treatment, the time and aggressiveness of surgery, and the role of adjuvant treatment.
Watchful waiting until progression may be an acceptable option in selected patients, however
surgical resection often results in improved outcomes and symptom control, particularly
tumor-related epilepsy[4–6], which is of especial interest due to the higher rate of seizures in
isocitrate dehydrogenase (IDH) mutant tumors[7].
Since 2016 molecular markers have been included in the classification[1]. This has trans-
lated into treatment decisions; presence of IDH mutation, 1p/19q co-deletion, ATRX expres-
sion, and TERT promoter mutation are used in diagnosis and provide prognosis estimates[8,
9]. Other factors such as older age (>40 years), incomplete bulk tumor resection, or having an
unfavorable molecular profile, such as IDH wild type, are considered in treatment decisions
for possible radiation and chemotherapy[10–13]. An established standard of care has not been
defined, and treatment strategies often differ among physicians. Our analysis describes the
prognosis and therapeutic patterns of care for diffuse gliomas in American College of Surgeons
Commission on Cancer (CoC)-accredited hospitals in the United States using the National
Cancer Database (NCDB).
Methods
NCDB is a joint program of the American College of Surgeons Commission on Cancer (CoC)
and the American Cancer Society that collects cases from over 1,500 CoC-accredited hospitals.
With over 34 million cases, it is the largest cancer database in the United States. Data collection
methods, characteristics of participating hospitals and patients, and assessment of data quality
have been described elsewhere, and has been used extensively in treatment description of pri-
mary brain tumors[14, 15].
We used the 2015 NCDB brain/central nervous system participant user file, which includes
cases from 2004 to 2015. Institutional Review Board approval was obtained as exception as
determined by the University of Kentucky.
Cases of diffuse glioma were identified using the International Classification of Disease for
Oncology (ICD-03) histology codes 9380–9382, 9400, 9401, 9410, 9411, 9420, 9421, 9424,
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9425, 9431, 9450, 9451, 9460. Patients with diagnosis of WHO grade I, III, IV, or not reported,
and patients younger than 18 years were excluded from the analysis.
Demographic variables that were analyzed include age at diagnosis, sex, race, Hispanic ori-
gin, primary payer status, median income, education status, and urban/rural residence. Living
area, as determined by the zip code of the patient recorded at the time of diagnosis was used to
classify patients as urban or rural, as defined by the United States Department of Agriculture
Economic Research Service[16]. Charlson-Deyo score[17] was used to assess patient comor-
bidities and was categorized as 0, 1, 2, or 3, as available in NCDB. Tumor location was
defined as midline (brainstem, spine, and ventricles not otherwise specified), cerebrum (cere-
brum and lobes), or other (including meninges, brain, and nervous system not otherwise spec-
ified). Education was assessed by the percentage of non-high school graduates in the patient
zip code at the time of diagnosis ( 7%, 7–12.9%, 13–20.9%, 21%).
Disease characteristics included in our analyses were primary site location, histology group,
chromosome 1p, and chromosome 19q loss of heterozygosity. Histology groups were divided
into astrocytic (9400, 9401, 9410, 9411, 9420, 9421, 9424, 9425), oligodendroglial (9450, 9451,
9460), and mixed (9380, 9381, 9382) as NCDB uses the WHO 2007 classification. 1p/19q co-
deletion status was available for cases diagnosed after 2010. Co-deletion was defined as having
both chromosomal arm deletions as reported in the Collaborative Stage Site-Specific Factors
by NCDB, cases negative for both chromosome deletions were defined as negative, and
patients with only one deletion reported were considered incomplete. Treatment received was
assessed as first course of treatment at any CoC facility, as previously described by our group
[18].
Statistical analysis
Chi square was performed for categorical variables. Age groups cutoff were determined based
on historical reports[10, 11] and increased mortality cutoffs using area under the curve. Sur-
vival and risk of mortality was assessed as previously described by our group using Kaplan
Meier and Cox proportional hazards models[18]. The level of statistical significance was set at
0.05 for all tests conducted, and all analyses were performed with SAS software version 9.4
(SAS Statistical Institute, Cary, North Carolina).
Results
A total of 13,621 cases were identified. The median age at diagnosis was 41 years (range: 18–
90) and 56% were male. Race was collected for 98.5% of the patients and was grouped in white,
black, and others. The most common race was white (88.5%), followed by black (6.1%), and
other races (3.9%). Hispanic origin was available for 93.6% of the patients, with 7.5% identified
as Hispanic. Hispanic origin was more common in younger age groups. Younger patients had
a higher proportion of blacks and other races (Table 1), that may represent demographic
trends in the United States, independent of tumor biology. Eighty-six percent had a Charlson-
Deyo score (measurement of co-morbidities) of zero, while 1% had a score3. Charlson-
Deyo score increased with increasing age but did not vary by histological groups or molecular
determinants (Table 2 and Table 3).
Astrocytic histology included 6,050 (44.4%) patients, oligodendroglial included 4,776
(35.1%), and mixed comprised 2,795 (20.5%) patients (Table 2). Gender distribution and His-
panic origin were not different among histology groups. Black race was more common among
astrocytic tumors (7.2%). The most common primary site location was the cerebrum (79.9%),
followed by “other” (16.6%), and midline (3.5%). 1p/19q co-deletion status was unknown in
9,617 patients (84.6%), reported as co-deleted in 901 (6.6%), non-co-deleted in 1,003 (7.4%),
Treatment and outcomes of low-grade gliomas
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and incomplete in 196 (1.4%) patients (Table 3). 1p/19q co-deletion testing is only available
after 2010 with an increasing tendency. Patients with 1p/19q co-deletion were significantly
younger than the non-co-deleted or incomplete groups, with a median age of 37 years
(p<0.01). Gender and Hispanic distribution were similar among all groups (Table 1, Table 2)
in a comparison of molecular factors (p = 0.98). A higher frequency of patients with 1p/19q
Table 1. Characteristics of the study population, by age group.
18–40
N = 6656
41–60
N = 5113
60
N = 1852
All
N = 13621
p-value
Gender Male 3767 (56.6%) 2890 (56.5%) 973 (52.5%) 7630 (56.0%) < .01
Female 2889 (43.4%) 2223 (43.5%) 879 (47.5%) 5991 (44.0%)
Race White 5798 (87.1%) 4568 (89.3%) 1685 (91.0%) 12051 (88.5%) < .01
Black 438 (6.6%) 302 (5.9%) 97 (5.2%) 837 (6.1%)
Other 315 (4.7%) 166 (3.2%) 52 (2.8%) 533 (3.9%)
Unknown 105 (1.6%) 77 (1.5%) 18 (1.0%) 200 (1.5%)
Hispanic Unknown 407 (6.1%) 335 (6.6%) 126 (6.8%) 868 (6.4%) < .01
No 5644 (84.8%) 4447 (87.0%) 1640 (88.6%) 11731 (86.1%)
Yes 605 (9.1%) 331 (6.5%) 86 (4.6%) 1022 (7.5%)
Tumor location NOS 997 (15.0%) 885 (17.3%) 376 (20.3%) 2258 (16.6%) < .01
Cerebrum 5430 (81.6%) 4071 (79.6%) 1385 (74.8%) 10886 (79.9%)
Midline 229 (3.4%) 157 (3.1%) 91 (4.9%) 477 (3.5%)
Charlson- 0 6040 (90.7%) 4311 (84.3%) 1308 (70.6%) 11659 (85.6%) < .01
Deyo 1 456 (6.9%) 573 (11.2%) 375 (20.2%) 1404 (10.3%)
Score 2 130 (2.0%) 175 (3.4%) 121 (6.5%) 426 (3.1%)
3 30 (0.5%) 54 (1.1%) 48 (2.6%) 132 (1.0%)
Facility Unknown 6312 (94.8%) 0 (0.0%) 0 (0.0%) 6312 (46.3%) < .01
Type Community 143 (2.1%) 2252 (44.0%) 963 (52.0%) 3358 (24.7%)
Academic 201 (3.0%) 2861 (56.0%) 889 (48.0%) 3951 (29.0%)
Living area Unknown 215 (3.2%) 205 (4.0%) 83 (4.5%) 503 (3.7%) < .01
Metro 5441 (81.7%) 4075 (79.7%) 1425 (76.9%) 10941 (80.3%)
Rural 1000 (15.0%) 833 (16.3%) 344 (18.6%) 2177 (16.0%)
Treatment Unknown 413 (6.2%) 265 (5.2%) 79 (4.3%) 757 (5.6%) < .01
None 432 (6.5%) 416 (8.1%) 261 (14.1%) 1109 (8.1%)
RT+CT+S 604 (9.1%) 658 (12.9%) 193 (10.4%) 1455 (10.7%)
RT+CT 280 (4.2%) 402 (7.9%) 232 (12.5%) 914 (6.7%)
RT+S 680 (10.2%) 654 (12.8%) 235 (12.7%) 1569 (11.5%)
CT+S 426 (6.4%) 393 (7.7%) 77 (4.2%) 896 (6.6%)
S only 3397 (51.0%) 1797 (35.1%) 464 (25.1%) 5658 (41.5%)
RT only 243 (3.7%) 343 (6.7%) 248 (13.4%) 834 (6.1%)
CT only 181 (2.7%) 185 (3.6%) 63 (3.4%) 429 (3.1%)
Insurance status Not Insured 585 (8.8%) 322 (6.3%) 40 (2.2%) 947 (7.0%) < .01
Private 4636 (69.7%) 3939 (77.0%) 570 (30.8%) 9145 (67.1%)
Medicaid 998 (15.0%) 420 (8.2%) 51 (2.8%) 1469 (10.8%)
Medicare 162 (2.4%) 227 (4.4%) 1144 (61.8%) 1533 (11.3%)
Other Gov’t 140 (2.1%) 95 (1.9%) 19 (1.0%) 254 (1.9%)
Unknown 135 (2.0%) 110 (2.2%) 28 (1.5%) 273 (2.0%)
NOS: Not otherwise specified; RT: Radiation therapy; CT: Chemotherapy; S: Surgery
https://doi.org/10.1371/journal.pone.0203639.t001
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co-deletion had a midline primary site location compared to those with 1p/19q non-co-deleted
(2.1% versus 0.3%, p<0.01).
Overall, the most common treatment modality was surgery (72.2%), followed by radiation
(36.0%), and chemotherapy (27.3%); 41.5% were treated with surgery only (Fig 1). Chemother-
apy and radiation were generally administered as adjuvant treatment; 6.1% of the patients
received radiation only and 3.1% received chemotherapy only. The maximal treatment
Table 2. Characteristics of the study population, by histology group.
Astrocytic
N = 6050
Mixed
N = 2795
Oligodendroglial
N = 4776
All
N = 13621
p-value
Gender Male 3381 (55.9%) 1593 (57.0%) 2656 (55.6%) 7630 (56.0%) 0.49
Female 2669 (44.1%) 1202 (43.0%) 2120 (44.4%) 5991 (44.0%)
Race White 5307 (87.7%) 2479 (88.7%) 4265 (89.3%) 12051 (88.5%) < .01
Black 434 (7.2%) 161 (5.8%) 242 (5.1%) 837 (6.1%)
Other 223 (3.7%) 109 (3.9%) 201 (4.2%) 533 (3.9%)
Unknown 86 (1.4%) 46 (1.6%) 68 (1.4%) 200 (1.5%)
Hispanic Unknown 355 (5.9%) 202 (7.2%) 311 (6.5%) 868 (6.4%) 0.14
No 5234 (86.5%) 2378 (85.1%) 4119 (86.2%) 11731 (86.1%)
Yes 461 (7.6%) 215 (7.7%) 346 (7.2%) 1022 (7.5%)
Tumor location NOS 1185 (19.6%) 460 (16.5%) 613 (12.8%) 2258 (16.6%) < .01
Cerebrum 4490 (74.2%) 2270 (81.2%) 4126 (86.4%) 10886 (79.9%)
Midline 375 (6.2%) 65 (2.3%) 37 (0.8%) 477 (3.5%)
Charlson- 0 5134 (84.9%) 2441 (87.3%) 4084 (85.5%) 11659 (85.6%) 0.07
Deyo 1 653 (10.8%) 251 (9.0%) 500 (10.5%) 1404 (10.3%)
Score 2 204 (3.4%) 73 (2.6%) 149 (3.1%) 426 (3.1%)
3 59 (1.0%) 30 (1.1%) 43 (0.9%) 132 (1.0%)
Facility Unknown 2720 (45.0%) 1458 (52.2%) 2134 (44.7%) 6312 (46.3%) < .01
Type Community 1660 (27.4%) 568 (20.3%) 1130 (23.7%) 3358 (24.7%)
Academic 1670 (27.6%) 769 (27.5%) 1512 (31.7%) 3951 (29.0%)
Living area Unknown 247 (4.1%) 114 (4.1%) 142 (3.0%) 503 (3.7%) 0.96
Metro 4834 (79.9%) 2237 (80.0%) 3870 (81.0%) 10941 (80.3%)
Rural 969 (16.0%) 444 (15.9%) 764 (16.0%) 2177 (16.0%)
Treatment Unknown 334 (5.5%) 146 (5.2%) 277 (5.8%) 757 (5.6%) < .01
None 629 (10.4%) 205 (7.3%) 275 (5.8%) 1109 (8.1%)
RT+CT+S 692 (11.4%) 348 (12.5%) 415 (8.7%) 1455 (10.7%)
RT+CT 588 (9.7%) 167 (6.0%) 159 (3.3%) 914 (6.7%)
RT+S 736 (12.2%) 377 (13.5%) 456 (9.5%) 1569 (11.5%)
CT+S 167 (2.8%) 168 (6.0%) 561 (11.7%) 896 (6.6%)
S only 2202 (36.4%) 1182 (42.3%) 2274 (47.6%) 5658 (41.5%)
RT only 565 (9.3%) 124 (4.4%) 145 (3.0%) 834 (6.1%)
CT only 137 (2.3%) 78 (2.8%) 214 (4.5%) 429 (3.1%)
Insurance status Not Insured 412 (6.8%) 209 (7.5%) 326 (6.8%) 947 (7.0%) < .01
Private 3859 (63.8%) 1896 (67.8%) 3390 (71.0%) 9145 (67.1%)
Medicaid 661 (10.9%) 329 (11.8%) 479 (10.0%) 1469 (10.8%)
Medicare 880 (14.5%) 255 (9.1%) 398 (8.3%) 1533 (11.3%)
Other Gov’t 112 (1.9%) 55 (2.0%) 87 (1.8%) 254 (1.9%)
Unknown 126 (2.1%) 51 (1.8%) 96 (2.0%) 273 (2.0%)
NOS: Not otherwise specified; RT: Radiation therapy; CT: Chemotherapy; S: Surgery
https://doi.org/10.1371/journal.pone.0203639.t002
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combination (radiation, chemotherapy, and surgery) was used in 10.7% of the patients. Other
combinations included radiation and surgery (11.5%), chemotherapy and surgery (6.6%), and
radiotherapy and chemotherapy (6.7%). Treatment modality was unknown in 5.6% of the
cases, and 8.1% received no treatment.
Table 3. Characteristics of the study population, by 1p/19q co-deletion status.
1p/19q
co-deleted
N = 901
Non
co-deleted
N = 1003
Incomplete
N = 196
Unknown
N = 11521
All
N = 13621
p-value
Age Median(years) 37 (18–83) 42 (18–80) 38 (18–79) 41 (18–90) 41 (18–90) < .01
Gender Male 511 (56.7%) 562 (56.0%) 110 (56.1%) 6447(56.0%) 7630(56.0%) 0.98
Female 390 (43.3%) 441 (44.0%) 86 (43.9%) 5074(44.0%) 5991(44.0%)
Race White 798 (88.6%) 902 (89.9%) 172 (87.8%) 10179(88.4%) 12051(88.5%) 0.02
Black 51 (5.7%) 46 (4.6%) 11 (5.6%) 729 (6.3%) 837 (6.1%)
Other 43 (4.8%) 50 (5.0%) 9 (4.6%) 431 (3.7%) 533 (3.9%)
Unknown 9 (1.0%) 5 (0.5%) 4 (2.0%) 182 (1.6%) 200 (1.5%)
Hispanic Unknown 23 (2.6%) 29 (2.9%) 7 (3.6%) 809 (7.0%) 868 (6.4%) <0.01
No 810 (89.9%) 907 (90.4%) 174 (88.8%) 9840 (85.4%) 11731(86.1%)
Yes 68 (7.5%) 67 (6.7%) 15 (7.7%) 872 (7.6%) 1022 (7.5%)
Tumor location NOS 118 (13.1%) 116 (11.6%) 35 (17.9%) 1989 (17.3%) 2258 (16.6%) < .01
Cerebrum 764 (84.8%) 884 (88.1%) 159 (81.1%) 9079 (78.8%) 10886(79.9%)
Midline 19 (2.1%) 3 (0.3%) 2 (1.0%) 453 (3.9%) 477 (3.5%)
Charlson- 0 774 (85.9%) 850 (84.7%) 168 (85.7%) 9867 (85.6%) 11659(85.6%) 0.76
Deyo 1 93 (10.3%) 101 (10.1%) 20 (10.2%) 1190 (10.3%) 1404 (10.3%)
Score 2 23 (2.6%) 38 (3.8%) 7 (3.6%) 358 (3.1%) 426 (3.1%)
3 11 (1.2%) 14 (1.4%) 1 (0.5%) 106 (0.9%) 132 (1.0%)
Facility Unknown 518 (57.5%) 443 (44.2%) 105 (53.6%) 5246 (45.5%) 6312 (46.3%) < .01
Type Community 135 (15.0%) 225 (22.4%) 38 (19.4%) 2960 (25.7%) 3358 (24.7%)
Academic 248 (27.5%) 335 (33.4%) 53 (27.0%) 3315 (28.8%) 3951 (29.0%)
Living area Unknown 26 (2.9%) 34 (3.4%) 4 (2.0%) 439 (3.8%) 503 (3.7%) 0.96
Metro 730 (81.0%) 797 (79.5%) 152 (77.6%) 9262 (80.4%) 10941(80.3%)
Rural 145 (16.1%) 172 (17.1%) 40 (20.4%) 1820 (15.8%) 2177 (16.0%)
Treatment Unknown 37 (4.1%) 48 (4.8%) 7 (3.6%) 665 (5.8%) 757 (5.6%) < .01
None 40 (4.4%) 40 (4.0%) 7 (3.6%) 1022 (8.9%) 1109 (8.1%)
RT+CT+S 138 (15.3%) 102 (10.2%) 31 (15.8%) 1184 (10.3%) 1455 (10.7%)
RT+CT 41 (4.6%) 36 (3.6%) 12 (6.1%) 825 (7.2%) 914 (6.7%)
RT+S 115 (12.8%) 79 (7.9%) 27 (13.8%) 1348 (11.7%) 1569 (11.5%)
CT+S 56 (6.2%) 181 (18.0%) 14 (7.1%) 645 (5.6%) 896 (6.6%)
S only 417 (46.3%) 444 (44.3%) 92 (46.9%) 4705 (40.8%) 5658 (41.5%)
RT only 39 (4.3%) 21 (2.1%) 2 (1.0%) 772 (6.7%) 834 (6.1%)
CT only 18 (2.0%) 52 (5.2%) 4 (2.0%) 355 (3.1%) 429 (3.1%)
Insurance status Not Insured 57 (6.3%) 68 (6.8%) 14 (7.1%) 808 (7.0%) 947 (7.0%) < .01
Private 639 (70.9%) 741 (73.9%) 136 (69.4%) 7629 (66.2%) 9145 (67.1%)
Medicaid 110 (12.2%) 98 (9.8%) 25 (12.8%) 1236 (10.7%) 1469 (10.8%)
Medicare 69 (7.7%) 72 (7.2%) 18 (9.2%) 1374 (11.9%) 1533 (11.3%)
Other Gov’t 20 (2.2%) 18 (1.8%) 1 (0.5%) 215 (1.9%) 254 (1.9%)
Unknown 6 (0.7%) 6 (0.6%) 2 (1.0%) 259 (2.2%) 273 (2.0%)
NOS: Not otherwise specified; RT: Radiation therapy; CT: Chemotherapy; S: Surgery
https://doi.org/10.1371/journal.pone.0203639.t003
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Fig 1. A. Chemotherapy, surgery, and radiation treatment receipt by 1p/19q co-deletion status. B. Chemotherapy,
surgery, and radiation treatment receipt by tumor location. C. Chemotherapy, surgery, and radiation treatment receipt
by age.
https://doi.org/10.1371/journal.pone.0203639.g001
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Treatment varied significantly with age (Table 1, Fig 1). The percent of patients undergoing
gross total resection decreased with increasing age. The use of adjuvant treatment was more
common in patients older than 40 years of age. Radiation only, radiation plus chemotherapy,
and no treatment were more common in patients over 60 years of age. Primary site location
was also a main determinant of treatment. Patients with midline lesions were less likely to be
treated with surgery alone and more commonly received radiation compared to primary site
location in the cerebrum. Interestingly, there was a higher percentage of astrocytic tumors
with midline primary site location (6.2%), compared to oligodendroglial tumors (0.8%). Oligo-
dendroglial tumors were also more likely to be located in the cerebrum compared to astrocytic
tumors.
Histological classification and molecular signatures had an impact on treatment receipt
(Table 2, Fig 1). Astrocytic tumors were more likely to be treated with radiation (43.8% versus
25.3%, p<0.01) while oligodendroglial tumors were more likely to receive surgery (79.9% ver-
sus 64.6%, p<0.01). Chemotherapy did not vary between both groups (p = 0.07). Adjuvant
treatment was more common in patients with astrocytic histology. Patients with oligodendrog-
lial histology were more likely to be treated with surgery only or chemotherapy plus surgery,
and were likely to receive radiation.
Radiation was more frequent in patients with 1p/19q co-deleted than in patients with non-
co-deleted status (37.3% versus 24.3%, p<0.01) (Table 3, Fig 1). Chemotherapy was more com-
mon in patients with 1p/19q non-co-deleted than in those with 1p/19q co-deleted (37.4% ver-
sus 28.1%, p<0.01). Combination therapy with radiation, chemotherapy plus surgery,
radiation plus chemotherapy, and radiation plus surgery were more common in patients with
1p/19q co-deleted (15.3%, 4.6%, and 12.8%, respectively). Combined chemotherapy and sur-
gery was more frequent in patients with 1p/19q non-co-deleted (18%).
Socioeconomic factors were assessed by insurance status, income level, and dwelling area.
The most common primary payer was private insurance (67.2%), followed by Medicare
(11.9%), and Medicaid (10.8%). Government insurance covered 23.9% of patients. The type of
primary payer varied with age and histologic groups. The majority of patients older than 60
years of age were covered by a type of government insurance (65.6%); primarily by Medicare
(61.8%). Private insurance was the main coverage in patients younger than 60 years while
17.3% were covered by any type of government insurance.
Median annual income was higher than $38,000 per year in 83.7% of patients. Socioeco-
nomic status was somewhat lower in patients with astrocytic tumors with lower income and
educational variables. Over 80% of the patients lived in metropolitan areas. The proportion of
patients living in rural areas was significantly higher for patients older than 60 years of age.
Histology groups were not associated with area of residence. Twenty-nine percent of patients
were reported to have received treatment in academic facilities, while 25% were treated in
community hospitals. The setting of the facility were patients were treated was unknown in
46.3%.
Survival
Median overall survival was 11.3 years. Survival varied by age, comorbidities, tumor location,
histology group, and molecular predictors; younger age, fewer comorbidities, oligodendroglial
histology, 1p/19q co-deletion, and cerebrum location had the best prognosis (Fig 2, Fig 3).
Median survival was greater in patients younger than 60 years of age (12.4 and 11.7 years for
<40 and 41–60 years old), compared to 2.2 years in patients older than 60 years. Median sur-
vival was not reached in patients with 1p/19q co-deleted low-grade gliomas. Median survival
Treatment and outcomes of low-grade gliomas
PLOS ONE | https://doi.org/10.1371/journal.pone.0203639 September 20, 2018 8 / 16
Fig 2. A. Survival by age group. B. Survival by 1p/19q co-deletion status. C. Survival by histology group.
https://doi.org/10.1371/journal.pone.0203639.g002
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Fig 3. Multivariate analysis for risk factor for mortality.
https://doi.org/10.1371/journal.pone.0203639.g003
Treatment and outcomes of low-grade gliomas
PLOS ONE | https://doi.org/10.1371/journal.pone.0203639 September 20, 2018 10 / 16
was 7.9 years in astrocytic tumors, 10 years in mixed histology, and was not reached in oligo-
dendroglial tumors.
We performed a multivariate analysis for risk factors for mortality (Fig 3). No treatment,
radiation only, and chemotherapy plus radiation were associated with increased risk of mortal-
ity. Male gender and black race, as compared to other, were associated with mortality. Medic-
aid and Medicare, and treatment in community facilities were associated with an increased
risk of death as compared to not insured.
Discussion
With the updated WHO of the nervous system in 2016 molecular profiling is required for
proper low-grade glioma classification[1]. Risk assessment is based on three groups: IDH
mutant tumors with 1p/19q co-deletion (predominantly oligodendroglial), IDH mutant with-
out 1p/19q co-deletion (predominantly astrocytic), and IDH wild-type tumors[19–21]. The
NCDB participant user file from 2004 to 2015 uses the WHO 2007 classification and some
molecular markers such as IDH status were not available in our study[16, 22]. Molecular pro-
filing reports were available after 2010 for 15.41% of the patients (Table 3), with an increasing
testing tendency.
In NCDB, overall survival was 11 years for all patients evaluated in CoC accredited hospitals
in the United States. This is comparable to the 13-year median survival reported by Buckner
et al. for high-risk patients receiving chemotherapy and radiation[23], and surpasses the
median survival reported in the majority of clinical trials, where it ranges from 7 to 9 years[24,
25]. Age 60 years and younger, 1p19q co-deletion, and oligodendroglial tumors were factors
associated with best survival in Kaplan-Meier analyses (Fig 2), and the results held in multivar-
iate proportional hazards models (Fig 3). Tumor location predicts the aggressiveness of treat-
ment due to the risk of functional impairment, that affects long-term survival[26]. Location,
such as midline location is also associated with molecular profiling characteristics associated
with poor prognosis[8, 27, 28].
Sociodemographic factors that include income, type of insurance, and facility location (aca-
demic versus community) are also associated with mortality. Patients treated in community
setting had an increased risk of mortality compared to patients treated in academic centers.
Similar findings have been described in glioblastoma[29], and suggests a role in access to
neuro-oncological care and the role of hospital volume and physician’s expertise in treatment
decisions. However, differences in risk factor exposure, disease severity, and population differ-
ences may also account for the observed results.
High-risk features for mortality in patients with diagnosis of low-grade gliomas include age
older than 40 years, tumor diameter greater than 6 cm, midline crossing, presence of neurolog-
ical deficit, and astrocytic histology[10]. Shaw et al. determined that patients defined as low
risk after gross total resection have a 50% risk of tumor progression at 5 years[11]. Based on
this, active surveillance remains an option for low risk patients[11]. However, due to the over-
lapping molecular prognostic factors, heterogeneity of these tumors, and challenges of com-
pleting clinical trials in a rarer and long surviving cancer, treatment recommendations remain
unestablished.
The longevity associated with these tumors provides concerns for long-term treatment-
associated toxicities. Treatment for brain tumors carries the concern for cognitive and func-
tional impairment[30], yet, not receiving treatment allowing for disease progression with asso-
ciated neurologic deficits and significant mortality.
Our results reflect that patients who receive chemotherapy plus surgery reach comparable
survival to those receiving surgery alone. Iwadate et al. found similar results in a nonrandomized
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trial[31], reporting equivalent outcomes in patients who underwent surgery alone versus those
who received adjuvant chemotherapy. The benefits of surgery with maximal safe resection are
established[32]. Our study with over 70% receiving surgery as first course of treatment demon-
strates the benefit of this and is in keeping with the literature, as surgical resection and the extent
of the resection has a significant survival benefit[33–35].
The recommendation of chemotherapy as adjuvant treatment is based on the extent of
resection, molecular features, and general state of patient. Chemotherapy is an option in
patients with a favorable molecular profile, and as a way to delay or forgo radiation[36].
Acknowledging gliomas as a wider brain involved disease than based on imaging, and that the
majority of tumors will progress without further treatment[37], the use of chemotherapy is an
option for selected high-risk patients to delay disease progression.
Triple combination therapy of surgery plus chemotherapy plus radiation was uncom-
mon (10.7%) but was associated with survival benefits. Retrospective analysis have shown
similar results[38]. Clinical trials have demonstrated that combination procarbazine,
lomustine and vincristine plus radiation improves outcomes in high risk patients[23, 25].
The type of chemotherapy agent received is not detailed in NCDB and is a limitation to
NCDB analysis. Procarbazine, lomustine and vincristine (PCV) combination or temozo-
lomide are the most used regimens[39], and are thought to be comparable. Adjuvant
temozolomide have demonstrated survival benefits in anaplastic gliomas and high-risk
low grade gliomas[39, 40].
Chemotherapy alone did not demonstrate survival benefits when compared to radiation
alone, or radiation plus chemotherapy in a phase III randomized clinical trials[41, 42], but was
associated with survival benefits in our analysis. Single center experiences and retrospective
analyses in unresectable tumors have shown some benefits[43, 44]. Chemotherapy alone may
be of benefit in selected patients in whom resection is not feasible.
The use of radiation alone and radiation plus chemotherapy was associated with
increased risk of mortality. Radiation use was significantly higher in patients with 1p/19q
co-deleted, older age, and astrocytic histology. These patients may have had less proper
tumor resective surgery due to their age and disease burden, and/or a more aggressive
clinical presentation. As to why 1p/19q co-deletion are more associated with radiation, it
is possibly due to late disease presentation, or being more aggressive on a treatment
responsive cancer. Although analyzing different clinical trials are problematic, the upfront
radiation alone trials without chemotherapy have median survival rates that are less than
a decade[39, 45, 46]. Early radiation has not shown to improve overall survival in random-
ized trials compared to patients who receive radiation at the time of progression[45]. The
use of radiation is associated with significant adverse events, mainly neurocognitive dete-
rioration, vasculopathies, and secondary malignancies[30, 47], and remains a topic of dis-
cussion as first line treatment.
NCDB provides long-term follow up and quality data on first course of treatment, but does
not include treatment associated complications, or cause of death. Molecular profiling and
tumor characteristics beyond our study are not widely available in the data, as well as individ-
ual patient assessments. However, our investigation provides an unique opportunity to evalu-
ate patterns of care across the largest cancer registry[15].
In summary, outcomes for low-grade gliomas in most of United States is at or beyond
reported in clinical trials and the use of adjuvant therapy may be associated with survival bene-
fits in selected high-risk patients. The role of radiation remains under investigation as first
course of treatment in all low-grade gliomas. Outcomes will continue to improve with further
understanding of tumor biology and behavior, improving patient selection.
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